1. Mutations in NOTCH2 in families with Hajdu-Cheney syndrome
- Author
-
Louis-Georges Ste-Marie, Jeremy Schwartzentruber, Kym M. Boycott, Aurore Caqueret, Jean-Pierre Fryns, Jacques L. Michaud, Jacek Majewski, Lysanne Patry, Mark E. Samuels, Hilde Van Esch, Fergus McKiernan, Janet Marcadier, and Ivo Marik
- Subjects
Male ,Hajdu–Cheney syndrome ,Osteoporosis ,Biology ,Hajdu-Cheney Syndrome ,medicine.disease_cause ,Acro-Osteolysis ,Alagille syndrome ,Genetics ,medicine ,Humans ,Exome ,Receptor, Notch2 ,Gene ,Genetics (clinical) ,Family Health ,Mutation ,Genetic disorder ,Hand ,medicine.disease ,Pedigree ,Radiography ,Face ,Female ,Hand Deformities, Congenital - Abstract
Hajdu-Cheney syndrome (HCS) is a rare genetic disorder whose hallmark is acro-osteolysis, shortening of terminal phalanges, and generalized osteoporosis. We assembled a cohort of seven families with the condition and performed whole exome resequencing on a selected set of affected patients. One protein-coding gene, NOTCH2, carried heterozygous truncating variants in all patients and their affected family members. Our results replicate recently published studies of HCS and further support this as the causal gene for the disorder. In total, we identified five novel and one previously reported mutation, all clustered near the carboxyl terminus of the gene, suggesting an allele specific genotype-phenotype effect since other mutations in NOTCH2 have been reported to cause a form of Alagille syndrome. Notch-mediated signaling is known to play a role in bone metabolism. Our results support a potential therapeutic role for Notch pathways in treatment of osteoporosis. Hum Mutat 32:1114–1117, 2011. ©2011 Wiley-Liss, Inc.
- Published
- 2011